Biovail Corp. and several generic drug makers reached an agreement that will delay sales of one form of the antidepressant Wellbutrin XL until next year. Teva Pharmaceutical Industries Ltd., with partners Anchen Pharmaceuticals and Impax Laboratories, will have an exclusive license to sell a generic version of the 300-milligram Wellbutrin until mid-June.

Related Summaries